• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vertex Pharmaceuticals (NQ: VRTX )

    495.91 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 156
    Open 495.91
    Bid (Size) 495.01 (1)
    Ask (Size) 504.11 (2)
    Prev. Close 495.91
    Today's Range 495.91 - 495.91
    52wk Range 340.20 - 498.77
    Shares Outstanding 259,428,394
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Gene Editing Stocks Shaping the Future of Medicine
    Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions 
    Via InvestorPlace
    2 Historically Flawless Metrics Suggest the Stock Market Can Plunge: Here Are 3 Stocks I've Sold Ahead of What May Be a Big Move for Wall Street
    Neither of these predictive indicators has ever been wrong when back-tested for more than 150 years! 
    Via The Motley Fool

    Performance

    YTD
    +20.69%
    +20.69%
    1 Month
    +4.41%
    +4.41%
    3 Month
    +24.00%
    +24.00%
    6 Month
    +12.68%
    +12.68%
    1 Year
    +38.89%
    +38.89%

    More News

    Read More
    3 Monster Stocks in the Making to Buy Right Now
    Via The Motley Fool
    The 3 Best Neuroscience Biotech Stocks to Buy Now
    Via InvestorPlace
    Looking for growth without the hefty price tag? Consider NASDAQ:VRTX.
    Via Chartmill
    Forecasting The Future: 13 Analyst Projections For Vertex Pharmaceuticals
    Via Benzinga
    Check Out What Whales Are Doing With VRTX
    Via Benzinga
    Why the quality investor may take a look at NASDAQ:VRTX.
    Via Chartmill
    3 Gene Editing Stocks That Could Grow Your Wealth
    Via InvestorPlace
    Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
    Via The Motley Fool
    Bull Market and Beyond: 2 Stocks Just Waiting to Soar
    Via The Motley Fool
    Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
    Via The Motley Fool
    Got $1,000? 2 Incredible Growth Stocks to Buy and Hold Forever
    Via The Motley Fool
    The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
    Via InvestorPlace
    Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
    Via Talk Markets
    3 No-Brainer Stocks to Buy in July
    Via The Motley Fool
    3 Pharma Stocks Already Ushering in the Next Biotech Boom
    Via InvestorPlace
    Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).
    Via The Motley Fool
    The 3 Best Biotech Stocks to Buy in July 2024
    Via InvestorPlace
    1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever
    Via The Motley Fool
    Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
    Via The Motley Fool
    Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
    Via The Motley Fool
    3 Top-Rated Gene Editing Stocks Actually Making Money
    Via InvestorPlace
    Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
    Via MarketBeat
    Topics ETFs
    Exposures COVID-19
    Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.